デフォルト表紙
市場調査レポート
商品コード
1061275

世界の肺動脈性肺高血圧症(PAH)市場:考察と予測 (2028年まで)

Global Pulmonary Arterial Hypertension (PAH) Market Insights and Forecast to 2028

出版日: | 発行: QYResearch | ページ情報: 英文 95 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
世界の肺動脈性肺高血圧症(PAH)市場:考察と予測 (2028年まで)
出版日: 2022年03月01日
発行: QYResearch
ページ情報: 英文 95 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、肺動脈性肺高血圧症(PAH) (Pulmonary Arterial Hypertension (PAH)) 市場について調査しており、市場規模や動向の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析:タイプ別
    • 世界の肺動脈性肺高血圧症(PAH)の市場規模成長率:タイプ別, 2017 VS 2021 VS 2028
    • Prostacyclin and Prostacyclin Analogs
    • SGC Stimulators
    • ERA
    • PDE-5
  • 市場:アプリケーション別
    • 世界の肺動脈性肺高血圧症(PAH)の市場規模成長率:アプリケーション別, 2017 VS 2021 VS 2028
    • Hospital
    • Clinic
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界の肺動脈性肺高血圧症(PAH)の市場展望 (2017-2028)
  • 肺動脈性肺高血圧症(PAH)の市場成長トレンド:地域別
    • 肺動脈性肺高血圧症(PAH) 市場規模:地域別: 2017 VS 2021 VS 2028
    • 肺動脈性肺高血圧症(PAH)の市場規模実績:地域別 (2017-2022)
    • 肺動脈性肺高血圧症(PAH)の市場規模予測:地域別 (2023-2028)
  • 肺動脈性肺高血圧症(PAH) 市場動向
    • 肺動脈性肺高血圧症(PAH) 業界動向
    • 肺動脈性肺高血圧症(PAH) 市場の促進要因
    • 肺動脈性肺高血圧症(PAH) 市場の課題
    • 肺動脈性肺高血圧症(PAH) 市場の抑制要因

第3章 競合情勢:主要企業別

  • 世界の肺動脈性肺高血圧症(PAH)の上位企業:収益別
    • 世界の肺動脈性肺高血圧症(PAH)の上位企業:収益別 (2017-2022)
    • 世界の肺動脈性肺高血圧症(PAH)の収益シェア:企業別 (2017-2022)
  • 世界の肺動脈性肺高血圧症(PAH)の市場シェア:企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング:肺動脈性肺高血圧症(PAH)の収益
  • 世界の肺動脈性肺高血圧症(PAH) 市場集中度
    • 世界の肺動脈性肺高血圧症(PAH) 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業: 肺動脈性肺高血圧症(PAH)の収益 2021
  • 肺動脈性肺高血圧症(PAH)の主要企業の本社および事業エリア
  • 主要企業 肺動脈性肺高血圧症(PAH)の製品ソリューションおよびサービス
  • 市場参入時期: 肺動脈性肺高血圧症(PAH) 市場
  • M&A, 拡張計画

第4章 肺動脈性肺高血圧症(PAH) 内訳データ:タイプ別

  • 世界の肺動脈性肺高血圧症(PAH)の市場規模実績:タイプ別 (2017-2022)
  • 世界の肺動脈性肺高血圧症(PAH)の市場規模予測:タイプ別 (2023-2028)

第5章 肺動脈性肺高血圧症(PAH) 内訳データ:アプリケーション別

  • 世界の肺動脈性肺高血圧症(PAH)の市場規模実績:アプリケーション別 (2017-2022)
  • 世界の肺動脈性肺高血圧症(PAH)の市場規模予測:アプリケーション別 (2023-2028)

第6章 北米

  • 北米の肺動脈性肺高血圧症(PAH) 市場規模 (2017-2028)
  • 北米の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2017-2022)
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2023-2028)
    • 北米の肺動脈性肺高血圧症(PAH)の市場シェア:タイプ別 (2017-2028)
  • 北米の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2017-2022)
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2023-2028)
    • 北米の肺動脈性肺高血圧症(PAH)の市場シェア:アプリケーション別 (2017-2028)
  • 北米の肺動脈性肺高血圧症(PAH) 市場規模:国別
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:国別 (2017-2022)
    • 北米の肺動脈性肺高血圧症(PAH) 市場規模:国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州の肺動脈性肺高血圧症(PAH) 市場規模 (2017-2028)
  • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2017-2022)
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2023-2028)
    • 欧州の肺動脈性肺高血圧症(PAH)の市場シェア:タイプ別 (2017-2028)
  • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2017-2022)
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2023-2028)
    • 欧州の肺動脈性肺高血圧症(PAH)の市場シェア:アプリケーション別 (2017-2028)
  • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:国別
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:国別 (2017-2022)
    • 欧州の肺動脈性肺高血圧症(PAH) 市場規模:国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模 (2017-2028)
  • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:タイプ別
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2017-2022)
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2023-2028)
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH)の市場シェア:タイプ別 (2017-2028)
  • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2017-2022)
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2023-2028)
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH)の市場シェア:アプリケーション別 (2017-2028)
  • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:地域別
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:地域別 (2017-2022)
    • アジア太平洋地域 肺動脈性肺高血圧症(PAH) 市場規模:地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模 (2017-2028)
  • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2017-2022)
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2023-2028)
    • ラテンアメリカの肺動脈性肺高血圧症(PAH)の市場シェア:タイプ別 (2017-2028)
  • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2017-2022)
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2023-2028)
    • ラテンアメリカの肺動脈性肺高血圧症(PAH)の市場シェア:アプリケーション別 (2017-2028)
  • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:国別
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:国別 (2017-2022)
    • ラテンアメリカの肺動脈性肺高血圧症(PAH) 市場規模:国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模 (2017-2028)
  • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2017-2022)
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:タイプ別 (2023-2028)
    • 中東・アフリカの肺動脈性肺高血圧症(PAH)の市場シェア:タイプ別 (2017-2028)
  • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2017-2022)
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:アプリケーション別 (2023-2028)
    • 中東・アフリカの肺動脈性肺高血圧症(PAH)の市場シェア:アプリケーション別 (2017-2028)
  • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:国別
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:国別 (2017-2022)
    • 中東・アフリカの肺動脈性肺高血圧症(PAH) 市場規模:国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • Actelion
  • Gilead Sciences
  • United Therapeutics
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Arena

第12章 アナリストによる分析/結論

第13章 付録

図表

LIST OF TABLES

List of Tables

  • Table 1. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Prostacyclin and Prostacyclin Analogs
  • Table 3. Key Players of SGC Stimulators
  • Table 4. Key Players of ERA
  • Table 5. Key Players of PDE-5
  • Table 6. Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 7. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 8. Global Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022) & (US$ Million)
  • Table 9. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2017-2022)
  • Table 10. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 11. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region (2023-2028)
  • Table 12. Pulmonary Arterial Hypertension (PAH) Market Trends
  • Table 13. Pulmonary Arterial Hypertension (PAH) Market Drivers
  • Table 14. Pulmonary Arterial Hypertension (PAH) Market Challenges
  • Table 15. Pulmonary Arterial Hypertension (PAH) Market Restraints
  • Table 16. Global Pulmonary Arterial Hypertension (PAH) Revenue by Players (2017-2022) & (US$ Million)
  • Table 17. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Players (2017-2022)
  • Table 18. Global Top Pulmonary Arterial Hypertension (PAH) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2021)
  • Table 19. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Companies by Revenue (US$ Million) in 2021
  • Table 20. Global 5 Largest Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue (CR5 and HHI) & (2017-2022)
  • Table 21. Key Players Headquarters and Area Served
  • Table 22. Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
  • Table 23. Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
  • Table 24. Mergers & Acquisitions, Expansion Plans
  • Table 25. Global Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 26. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2017-2022)
  • Table 27. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 28. Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Type (2023-2028)
  • Table 29. Global Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 30. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Application (2017-2022)
  • Table 31. Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 32. Global Pulmonary Arterial Hypertension (PAH) Revenue Share by Application (2023-2028)
  • Table 33. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 34. North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 35. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 36. North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 37. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 38. North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 39. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 40. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 41. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 42. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 43. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 44. Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 45. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 46. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 47. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 48. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 49. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022) & (US$ Million)
  • Table 50. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2023-2028) & (US$ Million)
  • Table 51. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 52. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 53. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 54. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 55. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 56. Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 57. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022) & (US$ Million)
  • Table 58. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028) & (US$ Million)
  • Table 59. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022) & (US$ Million)
  • Table 60. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028) & (US$ Million)
  • Table 61. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022) & (US$ Million)
  • Table 62. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028) & (US$ Million)
  • Table 63. Actelion Company Details
  • Table 64. Actelion Business Overview
  • Table 65. Actelion Pulmonary Arterial Hypertension (PAH) Product
  • Table 66. Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 67. Actelion Recent Developments
  • Table 68. Gilead Sciences Company Details
  • Table 69. Gilead Sciences Business Overview
  • Table 70. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Product
  • Table 71. Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 72. Gilead Sciences Recent Developments
  • Table 73. United Therapeutics Company Details
  • Table 74. United Therapeutics Business Overview
  • Table 75. United Therapeutics Pulmonary Arterial Hypertension (PAH) Product
  • Table 76. United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 77. United Therapeutics Recent Developments
  • Table 78. GlaxoSmithKline Company Details
  • Table 79. GlaxoSmithKline Business Overview
  • Table 80. GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Product
  • Table 81. GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 82. GlaxoSmithKline Recent Developments
  • Table 83. Pfizer Company Details
  • Table 84. Pfizer Business Overview
  • Table 85. Pfizer Pulmonary Arterial Hypertension (PAH) Product
  • Table 86. Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 87. Pfizer Recent Developments
  • Table 88. Bayer Company Details
  • Table 89. Bayer Business Overview
  • Table 90. Bayer Pulmonary Arterial Hypertension (PAH) Product
  • Table 91. Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 92. Bayer Recent Developments
  • Table 93. Arena Company Details
  • Table 94. Arena Business Overview
  • Table 95. Arena Pulmonary Arterial Hypertension (PAH) Product
  • Table 96. Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022) & (US$ Million)
  • Table 97. Arena Recent Developments
  • Table 98. Research Programs/Design for This Report
  • Table 99. Key Data Information from Secondary Sources
  • Table 100. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Pulmonary Arterial Hypertension (PAH) Market Share by Type: 2021 VS 2028
  • Figure 2. Prostacyclin and Prostacyclin Analogs Features
  • Figure 3. SGC Stimulators Features
  • Figure 4. ERA Features
  • Figure 5. PDE-5 Features
  • Figure 6. Global Pulmonary Arterial Hypertension (PAH) Market Share by Application: 2021 VS 2028
  • Figure 7. Hospital Case Studies
  • Figure 8. Clinic Case Studies
  • Figure 9. Pulmonary Arterial Hypertension (PAH) Report Years Considered
  • Figure 10. Global Pulmonary Arterial Hypertension (PAH) Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 11. Global Pulmonary Arterial Hypertension (PAH) Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 12. Global Pulmonary Arterial Hypertension (PAH) Market Share by Region: 2021 VS 2028
  • Figure 13. Global Pulmonary Arterial Hypertension (PAH) Market Share by Players in 2021
  • Figure 14. Global Top Pulmonary Arterial Hypertension (PAH) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) as of 2021)
  • Figure 15. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
  • Figure 16. North America Pulmonary Arterial Hypertension (PAH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 17. North America Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Type (2017-2028)
  • Figure 18. North America Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Application (2017-2028)
  • Figure 19. North America Pulmonary Arterial Hypertension (PAH) Market Size Share by Country (2017-2028)
  • Figure 20. United States Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 21. Canada Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 22. Europe Pulmonary Arterial Hypertension (PAH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 23. Europe Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Type (2017-2028)
  • Figure 24. Europe Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Application (2017-2028)
  • Figure 25. Europe Pulmonary Arterial Hypertension (PAH) Market Size Share by Country (2017-2028)
  • Figure 26. Germany Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 27. France Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 28. U.K. Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 29. Italy Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 30. Russia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. Nordic Countries Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 32. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 33. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Type (2017-2028)
  • Figure 34. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Application (2017-2028)
  • Figure 35. Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Share by Region (2017-2028)
  • Figure 36. China Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 37. Japan Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 38. South Korea Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 39. Southeast Asia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 40. India Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 41. Australia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 42. Latin America Pulmonary Arterial Hypertension (PAH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 43. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Type (2017-2028)
  • Figure 44. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Application (2017-2028)
  • Figure 45. Latin America Pulmonary Arterial Hypertension (PAH) Market Size Share by Country (2017-2028)
  • Figure 46. Mexico Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 47. Brazil Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 48. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size YoY (2017-2028) & (US$ Million)
  • Figure 49. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Type (2017-2028)
  • Figure 50. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size Market Share by Application (2017-2028)
  • Figure 51. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Market Size Share by Country (2017-2028)
  • Figure 52. Turkey Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 53. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 54. UAE Pulmonary Arterial Hypertension (PAH) Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 55. Actelion Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 56. Gilead Sciences Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 57. United Therapeutics Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 58. GlaxoSmithKline Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 59. Pfizer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 60. Bayer Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 61. Arena Revenue Growth Rate in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed
目次

Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market

The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, Prostacyclin and Prostacyclin Analogs accounting for % of the Pulmonary Arterial Hypertension (PAH) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.

China Pulmonary Arterial Hypertension (PAH) market size is valued at US$ million in 2021, while the North America and Europe Pulmonary Arterial Hypertension (PAH) are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Pulmonary Arterial Hypertension (PAH) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pulmonary Arterial Hypertension (PAH) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pulmonary Arterial Hypertension (PAH) market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pulmonary Arterial Hypertension (PAH) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pulmonary Arterial Hypertension (PAH) market.

Global Pulmonary Arterial Hypertension (PAH) Scope and Market Size

Pulmonary Arterial Hypertension (PAH) market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • ERA
  • PDE-5

Segment by Application

  • Hospital
  • Clinic

By Company

  • Actelion
  • Gilead Sciences
  • United Therapeutics
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Arena

By Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Prostacyclin and Prostacyclin Analogs
    • 1.2.3 SGC Stimulators
    • 1.2.4 ERA
    • 1.2.5 PDE-5
  • 1.3 Market by Application
    • 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Hospital
    • 1.3.3 Clinic
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Pulmonary Arterial Hypertension (PAH) Market Perspective (2017-2028)
  • 2.2 Pulmonary Arterial Hypertension (PAH) Growth Trends by Region
    • 2.2.1 Pulmonary Arterial Hypertension (PAH) Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Pulmonary Arterial Hypertension (PAH) Historic Market Size by Region (2017-2022)
    • 2.2.3 Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Region (2023-2028)
  • 2.3 Pulmonary Arterial Hypertension (PAH) Market Dynamics
    • 2.3.1 Pulmonary Arterial Hypertension (PAH) Industry Trends
    • 2.3.2 Pulmonary Arterial Hypertension (PAH) Market Drivers
    • 2.3.3 Pulmonary Arterial Hypertension (PAH) Market Challenges
    • 2.3.4 Pulmonary Arterial Hypertension (PAH) Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue
    • 3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Players by Revenue (2017-2022)
    • 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Revenue Market Share by Players (2017-2022)
  • 3.2 Global Pulmonary Arterial Hypertension (PAH) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Pulmonary Arterial Hypertension (PAH) Revenue
  • 3.4 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio
    • 3.4.1 Global Pulmonary Arterial Hypertension (PAH) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Revenue in 2021
  • 3.5 Pulmonary Arterial Hypertension (PAH) Key Players Head office and Area Served
  • 3.6 Key Players Pulmonary Arterial Hypertension (PAH) Product Solution and Service
  • 3.7 Date of Enter into Pulmonary Arterial Hypertension (PAH) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Type

  • 4.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Type (2017-2022)
  • 4.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Type (2023-2028)

5 Pulmonary Arterial Hypertension (PAH) Breakdown Data by Application

  • 5.1 Global Pulmonary Arterial Hypertension (PAH) Historic Market Size by Application (2017-2022)
  • 5.2 Global Pulmonary Arterial Hypertension (PAH) Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
  • 6.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type
    • 6.2.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
    • 6.2.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
    • 6.2.3 North America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
  • 6.3 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application
    • 6.3.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
    • 6.3.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
    • 6.3.3 North America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
  • 6.4 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country
    • 6.4.1 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    • 6.4.2 North America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    • 6.4.3 U.S.
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
  • 7.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type
    • 7.2.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
    • 7.2.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
    • 7.2.3 Europe Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
  • 7.3 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application
    • 7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
    • 7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
    • 7.3.3 Europe Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
  • 7.4 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country
    • 7.4.1 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    • 7.4.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
  • 8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type
    • 8.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application
    • 8.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region
    • 8.4.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
  • 9.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type
    • 9.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
    • 9.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
    • 9.2.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
  • 9.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application
    • 9.3.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
    • 9.3.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
    • 9.3.3 Latin America Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
  • 9.4 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country
    • 9.4.1 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    • 9.4.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size (2017-2028)
  • 10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type
    • 10.2.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application
    • 10.3.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country
    • 10.4.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Actelion
    • 11.1.1 Actelion Company Details
    • 11.1.2 Actelion Business Overview
    • 11.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.1.4 Actelion Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.1.5 Actelion Recent Developments
  • 11.2 Gilead Sciences
    • 11.2.1 Gilead Sciences Company Details
    • 11.2.2 Gilead Sciences Business Overview
    • 11.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.2.4 Gilead Sciences Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.2.5 Gilead Sciences Recent Developments
  • 11.3 United Therapeutics
    • 11.3.1 United Therapeutics Company Details
    • 11.3.2 United Therapeutics Business Overview
    • 11.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.3.4 United Therapeutics Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.3.5 United Therapeutics Recent Developments
  • 11.4 GlaxoSmithKline
    • 11.4.1 GlaxoSmithKline Company Details
    • 11.4.2 GlaxoSmithKline Business Overview
    • 11.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.4.4 GlaxoSmithKline Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.4.5 GlaxoSmithKline Recent Developments
  • 11.5 Pfizer
    • 11.5.1 Pfizer Company Details
    • 11.5.2 Pfizer Business Overview
    • 11.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.5.4 Pfizer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.5.5 Pfizer Recent Developments
  • 11.6 Bayer
    • 11.6.1 Bayer Company Details
    • 11.6.2 Bayer Business Overview
    • 11.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.6.4 Bayer Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.6.5 Bayer Recent Developments
  • 11.7 Arena
    • 11.7.1 Arena Company Details
    • 11.7.2 Arena Business Overview
    • 11.7.3 Arena Pulmonary Arterial Hypertension (PAH) Introduction
    • 11.7.4 Arena Revenue in Pulmonary Arterial Hypertension (PAH) Business (2017-2022)
    • 11.7.5 Arena Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer